Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

(2016) Ian Olver   Therapeutics and Clinical Risk Management

Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study

(2012) Costantine Albany et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

(2011) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial

(2010) Peter S. Grimison et al.   JNCI-Journal of the National Cancer Institute

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement

(2010) Lawrence H. Einhorn et al.   SUPPORTIVE CARE IN CANCER

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

(2009) Karin Jordan et al.   EUROPEAN JOURNAL OF CANCER

Understanding the concept of chemotherapy-related nausea: the patient experience

(2008) A. MOLASSIOTIS et al.   EUROPEAN JOURNAL OF CANCER CARE